Gene Therapy for the Treatment of Fanconi's Anemia Type C
| Status: | Completed |
|---|---|
| Conditions: | Anemia, Anemia, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 5 - Any |
| Updated: | 4/21/2016 |
| Start Date: | December 1993 |
| End Date: | February 2009 |
Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic Progenitors of Group C Patients
Fanconi's Anemia is an inherited disorder that can produce bone marrow failure. In addition,
some patients with Fanconi's anemia have physical defects usually involving the skeleton and
kidneys. The major problem for most patients is aplastic anemia, the blood counts for red
blood cells, white blood cells, and platelets are low because the bone marrow fails to
produce these cells. Some patients with Fanconi's anemia can develop leukemia or cancers of
other organs.
Many laboratory studies have suggested that Fanconi's anemia is caused by an inherited
defect in the ability of cells to repair DNA. Recently, the gene for one of the four types
of Fanconi's anemia, type C, has been identified. It is known that this gene is defective in
patients with Fanconi's anemia type C.
Researchers have conducted laboratory studies that suggest Fanconi's anemia type C may be
treatable with gene therapy. Gene therapy works by placing a normal gene into the cells of
patients with abnormal genes responsible for Fanconi's anemia type C. After the normal gene
is in place, new normal cells can develop and grow. Drugs can be given to these patients
kill the remaining abnormal cells. The new cells containing normal genes and will not be
harmed by these drugs.
The purpose of this study is to test whether researchers can safely place the normal
Fanconi's anemia type C gene into cells of patients with the disease. The gene will be
placed into special cells in the bone marrow called stem cells. These stem cells are
responsible for producing new red blood cells, white blood cells, and platelets.
some patients with Fanconi's anemia have physical defects usually involving the skeleton and
kidneys. The major problem for most patients is aplastic anemia, the blood counts for red
blood cells, white blood cells, and platelets are low because the bone marrow fails to
produce these cells. Some patients with Fanconi's anemia can develop leukemia or cancers of
other organs.
Many laboratory studies have suggested that Fanconi's anemia is caused by an inherited
defect in the ability of cells to repair DNA. Recently, the gene for one of the four types
of Fanconi's anemia, type C, has been identified. It is known that this gene is defective in
patients with Fanconi's anemia type C.
Researchers have conducted laboratory studies that suggest Fanconi's anemia type C may be
treatable with gene therapy. Gene therapy works by placing a normal gene into the cells of
patients with abnormal genes responsible for Fanconi's anemia type C. After the normal gene
is in place, new normal cells can develop and grow. Drugs can be given to these patients
kill the remaining abnormal cells. The new cells containing normal genes and will not be
harmed by these drugs.
The purpose of this study is to test whether researchers can safely place the normal
Fanconi's anemia type C gene into cells of patients with the disease. The gene will be
placed into special cells in the bone marrow called stem cells. These stem cells are
responsible for producing new red blood cells, white blood cells, and platelets.
Fanconi anemia (FA) is a rare genetic disorder characterized by progressive pancytopenia,
congenital abnormalities, and predisposition to malignancy. Therapy is currently limited to
allogeneic marrow transplantation; patients lacking a suitable donor usually die from
aplasia or acute leukemia. Recently, mutation in a novel gene named FACC (Fanconi anemia
C-complementing) has been identified as causing one type of FA. FACC mutations, which
introduce splicing errors or stop codons, have been identified in 15% of FA patients. We
have recently been successful in functional complementation of four FA cell lines using
retroviral vectors to transfer a copy of the normal FACC gene. We also analyzed the ability
of four viral vectors to functionally correct hematopoietic progenitor cells from a patient
bearing a splice donor mutation. As for the lymphoid cell lines, these CD34 enriched cells
were extremely sensitive to MMC. After injection of these progenitor cells with viral
vectors bearing normal FACC, the progenitors gave rise to increased numbers of colonies both
in the absence and presence of up to 5 nM MMC, whereas control cells were completely
destroyed by 1 nM MMC. In summary, we have demonstrated that: (1) retroviral vectors can be
engineered to transfer a normal FACC gene to FA(C) lymphoid cell lines and primary
hematopoietic cells; (2) introduction of a normal FACC gene into CD34+ progenitors markedly
enhances their growth in the absence and presence of MMC.
This study is designed to determine whether hematopoietic progenitors transduced with the
normal FACC gene can be re-infused safely into FA(C) patients. CD34+ cells obtained from
G-CSF mobilized peripheral blood will be transduced ex vivo over a 72 hour period in the
presence of IL-3, IL-6, and stem cell factor with the FACC retroviral vector. These
transduced cells will be re-infused into FA(C) patients. Patients will be monitored for
toxicities as well as evidence of successful gene transfer and expression. The procedure
will be repeated up to a total of 4 times with each treatment 2-4 months apart.
Theoretically, these rescued stem cells should have a selective growth advantage within the
hypoplastic FA marrow environment in vivo.
congenital abnormalities, and predisposition to malignancy. Therapy is currently limited to
allogeneic marrow transplantation; patients lacking a suitable donor usually die from
aplasia or acute leukemia. Recently, mutation in a novel gene named FACC (Fanconi anemia
C-complementing) has been identified as causing one type of FA. FACC mutations, which
introduce splicing errors or stop codons, have been identified in 15% of FA patients. We
have recently been successful in functional complementation of four FA cell lines using
retroviral vectors to transfer a copy of the normal FACC gene. We also analyzed the ability
of four viral vectors to functionally correct hematopoietic progenitor cells from a patient
bearing a splice donor mutation. As for the lymphoid cell lines, these CD34 enriched cells
were extremely sensitive to MMC. After injection of these progenitor cells with viral
vectors bearing normal FACC, the progenitors gave rise to increased numbers of colonies both
in the absence and presence of up to 5 nM MMC, whereas control cells were completely
destroyed by 1 nM MMC. In summary, we have demonstrated that: (1) retroviral vectors can be
engineered to transfer a normal FACC gene to FA(C) lymphoid cell lines and primary
hematopoietic cells; (2) introduction of a normal FACC gene into CD34+ progenitors markedly
enhances their growth in the absence and presence of MMC.
This study is designed to determine whether hematopoietic progenitors transduced with the
normal FACC gene can be re-infused safely into FA(C) patients. CD34+ cells obtained from
G-CSF mobilized peripheral blood will be transduced ex vivo over a 72 hour period in the
presence of IL-3, IL-6, and stem cell factor with the FACC retroviral vector. These
transduced cells will be re-infused into FA(C) patients. Patients will be monitored for
toxicities as well as evidence of successful gene transfer and expression. The procedure
will be repeated up to a total of 4 times with each treatment 2-4 months apart.
Theoretically, these rescued stem cells should have a selective growth advantage within the
hypoplastic FA marrow environment in vivo.
- INCLUSION CRITERIA:
Patients must meet the following criteria within 30 days prior to study entry (Day 0)
unless otherwise noted.
Males or females, age greater than or equal to 5 years of age.
Diagnosis of Fanconi anemia, complementation group C, as confirmed by 1) Diepoxybutane or
mitomycin C testing and 2) DNA analysis indicating FACC mutations.
Adequate baseline organ function as assessed by the following laboratory values within 30
days prior to study entry (day -30 to 0).
Adequate renal function with estimated creatinine clearance greater than 50 ml/min. (This
will be determined by serum creatinine and 24-hour urine creatinine ordered concurrently).
Adequate liver function with SGOT, SGPT and alkaline phosphatase less than or equal to 5
times the ULN (if transaminases greater than the upper limit of normal (ULN), patients
should have a hepatitis B surface antigen (HBsAG) test prior to study entry. Patients may
not enter the study if HBsAG is positive).
PT and PTT not more than 1.5 times the ULN.
Serum Amylase less than or equal to 1.5 times the ULN.
Bilirubin less than or equal to 3.0 mg/dL.
Triglyceride less than 400 mg/dl.
Ability to give informed consent.
Normal cardiac function by history and exam.
Resting transcutaneous oxygen saturation greater than 90 percent on room air.
Karnofsky Performance Status greater than or equal to 40.
Although there are no blood count criteria for inclusion in this study, preference will be
given to patients with significant marrow failure as reflected by anemia, neutropenia,
and/or thrombocytopenia. Furthermore, we intend to first enroll adults and older children,
to the extent possible, before enrolling younger children.
EXCLUSION CRITERIA:
Patients who meet any one of the following criteria will be excluded from study entry:
Patients presenting with acute leukemia or bone marrow aspirate revealing greater than 10
percent blasts.
Pregnant or lactating females (all patients must practice adequate birth control and
females of child-bearing potential must have a negative serum beta-HCG pregnancy test
(within Day -7 to Day 0).
Acute infection: any acute viral, bacterial, or fungal infection which requires specific
therapy. Acute therapy must have been completed within 14 days prior to study treatment.
Hepatitis-B surface antigen positive patients.
HIV-infected patients.
Acute medical problems such as ischemic heart or lung disease that may be considered an
unacceptable anesthetic or operative risk.
No patients with any underlying conditions which would contraindicate therapy with study
treatment (or allergies to reagents used in this study).
Patients less than 25 kg in weight .
Patients who elect bone marrow transplantation.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
